Meet MAIA’s Management Team

team

Frank Perabo, MD, PhD

President
Dr. Perabo is Co-Founder and President of the Company. He is a Life Science Executive with 20+ years of experience in drug development across all stages, from basic research to commercial products, with in-depth business expertise. In his previous role, he was the Founder and CEO of Barricade Therapeutics, Corp. Before that he served as ESSA Pharmaceuticals’ Chief Medical Officer and Executive Vice President of Development until January 2018.

Before ESSA, Dr. Perabo was Executive Director at Astellas Pharma Inc., Oncology Global Development, where he was instrumental in the development and worldwide approval of XTANDI® (Enzalutamide). Before that, he worked as Global Medical Lead in multiple preclinical and early clinical to Phase 3 development programs; successfully directing various projects at Astellas Europe including Myrbetriq®/BetmigaTM (Mirabegron) and VesomniTM. Previously, he co-founded a consulting company for early phase oncology drug development, and was member of a Management team at an Oncology Start-up CRO. Dr. Perabo has extensive experience with start-up companies, successfully translating academic research into clinical programs, as well as licensing activities. He obtained his medical training at the University of Munich, with clinical training in surgery and urology in Munich, Freiburg and Bonn after graduating magna cum laude . He obtained a PhD for his work on ‘signal transduction pathways’ in cancer biology from the University of Munich. He is a European board-certified urologist, and an Associate Professor at Bonn University, and member of several urologic and oncologic associations. Dr. Perabo has received multiple international awards in urology and oncology research.

Read More
team

Vlad Vitoc, MD, MBA

CEO
Dr. Vitoc is a biotech executive with a broad array of experience across commercial strategic analysis and planning and medical affairs, in which he has 20 years of experience. He has served on leadership teams in several Oncology companies and business units. He also has a track record of successful organizational capability building, talent recruiting and development, and functional leadership.

His experience includes managing and supporting over 20 early, launch, and mature stage compounds, amongst which targeted therapies and immune therapies, across more than 25 tumor types – amongst which colorectal cancer, hepatocellular carcinoma, lung cancer, breast cancer prostate cancer, renal cell carcinoma. In his previous role at Barricade Therapeutics, he served as the Chief Business Officer and SVP Medical Affairs, leading the capitalization efforts and the pharmaceutical business development activities.  At Puma Biotechnology, he served as VP Medical Affairs and built the Medical organization supporting the launch of NERLYNX (neratinib) in extended adjuvant breast cancer.  Before Puma, Dr. Vitoc was the Executive Medical Director for pipeline products at Incyte Corporation, establishing the medical affairs support for compounds transitioning from preclinical to phase I and II clinical trials.  Before that, he was Sr Medical Director at Astellas Pharma Inc., supporting the launch and development of XTANDI (enzalutamide), the life cycle management of TARCEVA (erlotinib), as well as pipeline compounds.  Earlier in his career, he served in commercial strategic analysis and planning leadership roles centered on life cycle management, business development, and forecasting at Cephalon Oncology, Novartis Oncology, Bayer Oncology, and Pharmacia & Upjohn.  He obtained his medical training at the University of Medicine and Pharmacy “Iuliu Hatieganu” in Cluj-Napoca, Romania, and his MBA at the University of South Carolina.

Read More
team

Leah DiMascio, PhD, PMP

COO
Dr. DiMascio serves as the company’s Chief Operating Officer and head of project management. She has over 10 years of experience in the biotech industry where she has successfully managed the development of multiple preclinical and clinical stage products as well as provided oversight of key business functions including project management, corporate budgeting, IT, human resources, and quality assurance.

Dr. DiMascio previously served as Senior Director, Project Management and Corporate Operations at ESSA Pharmaceuticals where she was instrumental in establishing the company’s Houston operations. Before ESSA, she was Senior Program Manager at Vermilllion, Inc. There, in addition to her program management responsibilities, she developed and implemented business planning processes and managed Vermillion’s relationships with all external collaborators and KOLs. Prior to Vermillion she held project management positions of increasing responsibility at Apocell and Emergent Biosolutions. Dr. DiMascio received her Ph.D. in Pharmacology and Cancer Biology from Duke University and her B.S. in Biology, Summa Cum Laude from Virginia Tech.

Read More
team

Joe Dillon, PHD, MBA

CFO
Dr. Dillon serves as the company’s Chief Financial Officer. He has over 30 years’ experience in the pharma/biotech industry covering finance, business development, transactions, and strategic planning in companies operating in the US and globally. He has held executive positions in several companies, including as CFO for both public and private corporations, where he has a proven track record of creating value.